Who Owns Sofwave?

Sofwave Medical was incorporated on January 27, 2015, in Yokneam Illit, Israel, by Eckhouse and Sverdlik. The founding premise was that high-frequency ultrasound could deliver skin lifting and wrinkle reduction without the downtime or safety compromises of existing energy-based devices.

The core invention is SUPERB, Synchronous Ultrasound Parallel Beam technology, which creates a controlled mid-dermal thermal effect to stimulate collagen remodeling while an integrated cooling system protects the skin surface. Early development focused on regulatory clearance and clinical validation rather than rapid commercialization.

The company received FDA clearance for its flagship indication, improvement of facial lines and wrinkles, and built out additional clearances covering eyebrow lifting and submental and neck laxity. Commercial launch built a practitioner base among dermatologists and plastic surgeons in the US, Europe, and Asia.

On May 18, 2021, Sofwave Medical listed on the Tel Aviv Stock Exchange. Revenue then grew rapidly from a small base: $21.8 million in 2021, $35.6 million in 2022, $50.3 million in 2023, $59.7 million in 2024, and $87.6 million in 2025, a 46.9 percent year-over-year increase. Trailing twelve-month revenue passed $104 million by mid-2026.

The company expanded its platform with Pure Impact VIP, a non-invasive muscle toning technology, broadening beyond skin into body aesthetics. Employee count reached 151 by late 2026, up roughly 20 percent year over year, reflecting continued commercial expansion.